CG Oncology (CGON) Financial Analysis & Valuation | Quarter Chart
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients wi... more
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a ... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $5.47B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Arthur Kuan |
| IPO Date | 2024-01-25 | CAGR | -20.97% |
| Employees | 142 | Website | cgoncology.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CGON chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $5.10B | P/E | -22.94 | Forward P/E | -20.43 | PEG | — |
| P/S | 52.84 | P/B | 0.31 | P/CF | -1.84 | P/FCF | -1.83 |
| Sales | $6.23M | Sales 1Y | 1030.31% | Sales 3Y | — | Sales 5Y | — |
| EPS | $-2.69 | EPS 1Y | 51.69% | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | 6.83% | EPS QoQ | 26.76% | Sales QoQ Avg | — | EPS QoQ Avg | 15.02% |
| Gross Margin | -82.69% | Operating Margin | -4056.18% | Profit Margin | -2333.32% | ROCE | -24.33% |
| ROA | -13% | ROE | -16% | Altman Z Score | 55.31 | Piotroski Score | 2 |
| Current Ratio | 22.22 | Quick Ratio | 22.2 | Cash Ratio | 0.42 | Op. CF Ratio | -0.98 |
| Debt/Equity | 0.01 | Debt/Assets | 0.01 | Lt Debt/Equity | 0.01 | Lt Debt/Cap. | 0.01 |
| Intrst Cov. | — | Inventory Turnover | 11.34 | Asset Turnover | 0.01 | Receivables Turnover | 14.94 |
| Enterprise Value | $5.10B | P/E Ratio | -22.94 |
| Forward P/E | -20.43 | PEG Ratio | — |
| P/S Ratio | 52.84 | P/B Ratio | 0.31 |
| P/CF Ratio | -1.84 | P/FCF Ratio | -1.83 |
| EPS | $-2.69 | EPS Growth 1Y | 51.69% |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 1030.31% | Gross Margin | -82.69% |
| Operating Margin | -4056.18% | Profit Margin | -2333.32% |
| ROE | -16% | ROA | -13% |
| ROCE | -24.33% | Current Ratio | 22.22 |
| Quick Ratio | 22.2 | Cash Ratio | 0.42 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | 55.31 | Piotroski Score | 2 |
CG Oncology (CGON) valuation & financials
CG Oncology (CGON) has a market capitalization of $5.47B and trades at a price-to-earnings ratio of -22.9. It operates in the Healthcare sector (Biotechnology).
CG Oncology's revenue grew +1030.3% over the last year.
CG Oncology's next earnings report is scheduled for November 13, 2026 (provider scheduled date); analysts estimate EPS of $-0.83. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)